Dermata Therapeutics Inc. announced that the Australian Patent Office has granted a patent for its DMT410 program aimed at treating hyperhidrosis. The patent, titled "Compositions for the treatment of skin conditions," is a significant addition to Dermata's global intellectual property portfolio, reinforcing the company's commitment to innovative treatments for hyperhidrosis. This marks the second granted patent for DMT410, which utilizes Spongilla technology to deliver botulinum toxin topically. Dermata is also collaborating with Revance to study DMT410 for axillary hyperhidrosis, with potential applications for palmar and plantar hyperhidrosis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.